Terns Pharmaceuticals, Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending September 30, 2020 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) decreased by NaN%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of Terns Pharmaceuticals, Inc.

Most recent Goodwill and Intangible Assets (Total)of TERN including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.0 $0.0 $0.0
2019 $0.0

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.